Pressure BioSciences, Inc. announced in an interview with renowned cannabis business authority Jeffrey Friedland that PBIO was now advancing into Phase 2 of commercialization of its revolutionarily-effective, UltraShear?-processed nanoemulsified CBD topical spray, transitioning from early, targeted sales and marketing efforts into rapid expansion plans for its nationwide and global distribution base. PBIO's President and CEO, Mr. Richard T. Schumacher explained in the interview: There has been significant noise in the CBD and broader cannabis markets from companies touting a nanoemulsion offering in the past few years, but none are able to match UltraShear's capability to deliver tightly controlled nano-droplet sizes in the sub-100 nm range, with rock-solid stability, easily and affordable scaled-up production efficiency, and elimination of the metal contamination resulting from the most commonly-used competitive technology. The company initially hand-picked a small, select group of retailers for its first round of efforts in the sale and distribution of the company?s Nano-CBD Topical Spray product, which allowed the company to explore and optimize factors like product formulation, CBD concentration targets, bottle and dispenser technology, product size and packaging configuration, pricing, and shipping logistics.

This first phase of activity was extremely productive in answering those questions. The company now have a confidently-designed product and an accumulation of powerful UltraShear Nano-CBD Topical Spray user testimonials. Mr. Schumacher continued: Effective this week, the company enter PBIO's Phase 2 of the company's Nano-CBD commercialization strategy with rapidly expanding efforts to welcome and integrate many additional retailers and wholesalers across the USA, while the company introduce and establish it uniquely fast-acting and potent Nano-CBD topical spray to the broader U.S. and global markets.

As the company had mentioned in recent news releases, independent research by a leading cannabis academic team has dramatically confirmed its UltraShear-processed Nano-CBD product to have uniquely differentiated performance over all existing known CBD products (compared to the gold standard of IV infusion), and The company anticipates the release of those results in a peer-reviewed scientific journal in the near future. Pressed by Mr. Friedman to discuss the expected impact of this announced Phase 2 upon PBIO's business results for the remainder of 2023 and beyond, Mr. Schumacher concluded: The company anticipates signing up over 20 retailers and wholesalers in the remainder of 2023, with an estimated incremental revenue impact of $2 million to $3 million over 2022 results. The company also plan to launch its UltraShear Nano-CBD OralSpray product this October 2023.

Over the next 12 months, the company?s goal is to sign and launch at least 50 new UltraShear Nano-CBD retailers and wholesalers, and to achieve at least $10 million in incremental revenue impact in 2024.